At Enzymotec's annual and extraordinary general meeting of shareholders, Enzymotec shareholders voted to approve the previously announced acquisition by Frutarom.

99.9% of Enzymotec shareholders approve of Frutarom acquisition

At Enzymotec's annual and extraordinary general meeting of shareholders, Enzymotec shareholders voted to approve the previously announced acquisition by Frutarom. 99.9% of votes cast at the meeting voted in favour of the merger.

Enzymotec and Frutarom entered into the merger agreement on October 28, 2017 providing for Frutarom to acquire Enzymotec.

Enzymotec has also reported that all of the regulatory approvals and clearances required for the acquisition have been obtained. Subject to fulfillment of certain customary closing conditions, the company expects the acquisition to be completed by mid-January 2018, following the expiration of a mandatory 30-day waiting period following the shareholder approval in accordance with Israeli law. At the closing of the acquisition, Enzymotec shareholders will have the right to receive US$11.90 in exchange for each Enzymotec ordinary share.

14 DEC 2017

At Enzymotec's annual and extraordinary general meeting of shareholders, Enzymotec shareholders voted to approve the previously announced acquisition by Frutarom.

99.9% of Enzymotec shareholders approve of Frutarom acquisition

At Enzymotec's annual and extraordinary general meeting of shareholders, Enzymotec shareholders voted to approve the previously announced acquisition by Frutarom. 99.9% of votes cast at the meeting voted in favour of the merger.

Enzymotec and Frutarom entered into the merger agreement on October 28, 2017 providing for Frutarom to acquire Enzymotec.

Enzymotec has also reported that all of the regulatory approvals and clearances required for the acquisition have been obtained. Subject to fulfillment of certain customary closing conditions, the company expects the acquisition to be completed by mid-January 2018, following the expiration of a mandatory 30-day waiting period following the shareholder approval in accordance with Israeli law. At the closing of the acquisition, Enzymotec shareholders will have the right to receive US$11.90 in exchange for each Enzymotec ordinary share.